Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589536560> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2589536560 endingPage "158" @default.
- W2589536560 startingPage "158" @default.
- W2589536560 abstract "158 Background: While combination chemotherapy involving fluoropyrimidines and platinum is currently considered a standard regimen in AGC, there has been a price to pay in terms of toxicity. Since the main goal of treatment in AGC remains palliation, the current multi-center phase III trial compares efficacy and safety of XELOX combination with those of X monotherapy in elderly patients with AGC. Methods: AGC Patients aged 70 years or older were randomized 1:1 to receive X (capecitabine 1000 mg/m2 bid po on D1-D14) or XELOX (capecitabine 1000 mg/m2 bid po on D1-D14 plus oxaliplatin 110 mg/m2 iv on D1). Treatment was repeated every 21 days until disease progression, unacceptable toxicity, or patient’s refusal. Primary endpoint was overall survival, and the target sample size was 200 eligible patients. This interim safety analysis contains toxicity data from the first 27 randomized patients. Results: Among the 27 patients (X: 13, XELOX 14), median age was 77 (range, 70-84) years and 24 patients had symptomatic (ECOG PS 1-2) disease. The arms of the study were balanced with respect to baseline characteristics. No treatment-related serious adverse events (SAEs) or unexpected toxicities were observed. The most frequent toxicities were anorexia, fatigue, anemia, and hand-foot skin reactions. Fatigue and sensory neuropathy were more common in XELOX than X patients. QOL data showed no significant differences between the two arms. Conclusions: Our data indicate that the addition of oxaliplatin does not add to the toxicity of single agent capecitabine as first-line chemotherapy in elderly (age ≥70 years) AGC patients. The accrual is currently ongoing (ClinicalTrials.gov, NCT01470742). Clinical trial information: NCT01470742." @default.
- W2589536560 created "2017-03-03" @default.
- W2589536560 creator A5005933314 @default.
- W2589536560 creator A5011928803 @default.
- W2589536560 creator A5015598872 @default.
- W2589536560 creator A5019406140 @default.
- W2589536560 creator A5032561728 @default.
- W2589536560 creator A5045587524 @default.
- W2589536560 creator A5048058078 @default.
- W2589536560 creator A5057146015 @default.
- W2589536560 creator A5060913021 @default.
- W2589536560 creator A5062021313 @default.
- W2589536560 creator A5063326703 @default.
- W2589536560 creator A5065244228 @default.
- W2589536560 date "2014-01-20" @default.
- W2589536560 modified "2023-09-25" @default.
- W2589536560 title "Interim safety analysis from a randomized, open-label, multicenter, phase III trial of capecitabine plus oxaliplatin (XELOX) versus capecitabine (X) as first-line chemotherapy in elderly patients with advanced gastric cancer (AGC)." @default.
- W2589536560 doi "https://doi.org/10.1200/jco.2014.32.3_suppl.158" @default.
- W2589536560 hasPublicationYear "2014" @default.
- W2589536560 type Work @default.
- W2589536560 sameAs 2589536560 @default.
- W2589536560 citedByCount "1" @default.
- W2589536560 countsByYear W25895365602016 @default.
- W2589536560 crossrefType "journal-article" @default.
- W2589536560 hasAuthorship W2589536560A5005933314 @default.
- W2589536560 hasAuthorship W2589536560A5011928803 @default.
- W2589536560 hasAuthorship W2589536560A5015598872 @default.
- W2589536560 hasAuthorship W2589536560A5019406140 @default.
- W2589536560 hasAuthorship W2589536560A5032561728 @default.
- W2589536560 hasAuthorship W2589536560A5045587524 @default.
- W2589536560 hasAuthorship W2589536560A5048058078 @default.
- W2589536560 hasAuthorship W2589536560A5057146015 @default.
- W2589536560 hasAuthorship W2589536560A5060913021 @default.
- W2589536560 hasAuthorship W2589536560A5062021313 @default.
- W2589536560 hasAuthorship W2589536560A5063326703 @default.
- W2589536560 hasAuthorship W2589536560A5065244228 @default.
- W2589536560 hasConcept C121608353 @default.
- W2589536560 hasConcept C126322002 @default.
- W2589536560 hasConcept C141071460 @default.
- W2589536560 hasConcept C143998085 @default.
- W2589536560 hasConcept C168563851 @default.
- W2589536560 hasConcept C197934379 @default.
- W2589536560 hasConcept C203092338 @default.
- W2589536560 hasConcept C2776694085 @default.
- W2589536560 hasConcept C2777909004 @default.
- W2589536560 hasConcept C2778336483 @default.
- W2589536560 hasConcept C2780962732 @default.
- W2589536560 hasConcept C2781413609 @default.
- W2589536560 hasConcept C526805850 @default.
- W2589536560 hasConcept C61943457 @default.
- W2589536560 hasConcept C71924100 @default.
- W2589536560 hasConcept C90924648 @default.
- W2589536560 hasConceptScore W2589536560C121608353 @default.
- W2589536560 hasConceptScore W2589536560C126322002 @default.
- W2589536560 hasConceptScore W2589536560C141071460 @default.
- W2589536560 hasConceptScore W2589536560C143998085 @default.
- W2589536560 hasConceptScore W2589536560C168563851 @default.
- W2589536560 hasConceptScore W2589536560C197934379 @default.
- W2589536560 hasConceptScore W2589536560C203092338 @default.
- W2589536560 hasConceptScore W2589536560C2776694085 @default.
- W2589536560 hasConceptScore W2589536560C2777909004 @default.
- W2589536560 hasConceptScore W2589536560C2778336483 @default.
- W2589536560 hasConceptScore W2589536560C2780962732 @default.
- W2589536560 hasConceptScore W2589536560C2781413609 @default.
- W2589536560 hasConceptScore W2589536560C526805850 @default.
- W2589536560 hasConceptScore W2589536560C61943457 @default.
- W2589536560 hasConceptScore W2589536560C71924100 @default.
- W2589536560 hasConceptScore W2589536560C90924648 @default.
- W2589536560 hasIssue "3_suppl" @default.
- W2589536560 hasLocation W25895365601 @default.
- W2589536560 hasOpenAccess W2589536560 @default.
- W2589536560 hasPrimaryLocation W25895365601 @default.
- W2589536560 hasRelatedWork W2077919698 @default.
- W2589536560 hasRelatedWork W2160763249 @default.
- W2589536560 hasRelatedWork W2279780216 @default.
- W2589536560 hasRelatedWork W2340079215 @default.
- W2589536560 hasRelatedWork W2347780995 @default.
- W2589536560 hasRelatedWork W2361031241 @default.
- W2589536560 hasRelatedWork W2418334170 @default.
- W2589536560 hasRelatedWork W2589536560 @default.
- W2589536560 hasRelatedWork W3089110714 @default.
- W2589536560 hasRelatedWork W3110292103 @default.
- W2589536560 hasVolume "32" @default.
- W2589536560 isParatext "false" @default.
- W2589536560 isRetracted "false" @default.
- W2589536560 magId "2589536560" @default.
- W2589536560 workType "article" @default.